{"id":4930,"date":"2025-11-20T23:50:08","date_gmt":"2025-11-20T13:50:08","guid":{"rendered":"\/eu-uk\/?p=4930"},"modified":"2025-11-20T23:50:08","modified_gmt":"2025-11-20T13:50:08","slug":"remplir-nerve-sparing-prostate-cancer-surgery-commercial-opportunity-gathers-momentum","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/11\/20\/remplir-nerve-sparing-prostate-cancer-surgery-commercial-opportunity-gathers-momentum\/","title":{"rendered":"Remplir\u2122 Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum"},"content":{"rendered":"<p><span data-contrast=\"auto\">Momentum is growing\u00a0for\u00a0Remplir\u2122\u00a0in nerve-sparing prostate cancer surgery,\u00a0with around 100 surgeries now performed using\u00a0the flagship nerve repair device.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Adoption among Australian urologists is accelerating,\u00a0with\u00a0Remplir\u00a0being used\u00a0to support postoperative nerve protection and recovery. Surgeons are applying the collagen wrap during robotic-assisted radical prostatectomy with the aim of improving erectile function and urinary continence following surgery.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This emerging application\u00a0represents\u00a0a significant commercial opportunity, with the potential to expand\u00a0Orthocell\u2019s\u00a0U.S. total addressable market from US$1.6B to<\/span><b><span data-contrast=\"auto\">\u00a0<\/span><\/b><span data-contrast=\"auto\">approximately US$2B<\/span><span data-contrast=\"auto\">.<\/span><\/p>\n<p><span data-contrast=\"auto\">To support this opportunity,\u00a0Orthocell\u00a0is setting up a commercialisation advisory board and investing in further research to strengthen the scientific evidence base for this new application of\u00a0Remplir.<\/span><\/p>\n<p><span data-contrast=\"auto\">Initial clinical performance data from nerve-sparing procedures using\u00a0Remplir\u00a0across Australia will be released once compiled.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Orthocell\u00a0CEO and MD, Paul Anderson, said:\u00a0<\/span><br \/>\n<i><span data-contrast=\"auto\">\u201cWe\u2019re thrilled to see\u00a0Remplir\u00a0being adopted by urologists in Australia for nerve-sparing prostate surgery, reflecting its broader potential in peripheral nerve protection and repair. This\u00a0demonstrates\u00a0the utility of the product and\u00a0represents\u00a0the potential for a meaningful step forward in improving patient outcomes following these complex surgeries.\u201d<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/cdn-api.markitdigital.com\/apiman-gateway\/ASX\/asx-research\/1.0\/file\/2924-03025491-6A1298011&amp;v=undefined?utm_source=mailchimp&amp;utm_medium=edm&amp;utm_campaign=asx\"><span data-contrast=\"auto\">Read the ASX release<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Momentum is growing\u00a0for\u00a0Remplir\u2122\u00a0in nerve-sparing prostate cancer surgery,\u00a0with around 100 surgeries now performed using\u00a0the flagship nerve repair device.<\/p>\n","protected":false},"author":2,"featured_media":4856,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4930"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4930\/revisions"}],"predecessor-version":[{"id":4931,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4930\/revisions\/4931"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4856"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4930"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}